Global GLP-1/GIP Dual Receptor Agonist Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global GLP-1/GIP Dual Receptor Agonist market size was valued at US$ 34075 million in 2025 and is forecast to a readjusted size of US$ 70279 million by 2032 with a CAGR of 10.7% during review period.
In 2025, global GLP-1/GIP Dual Receptor Agonist production reached approximately 188.95 M Units, with an average global market price of around 175.26 USD per Unit.
A GLP-1/GIP dual receptor agonist is a single therapeutic agent (usually a peptide) designed to activate both the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR). By stimulating these two incretin pathways together, it aims to improve metabolic control—typically by enhancing glucose-dependent insulin secretion, reducing glucagon when appropriate, slowing gastric emptying, and decreasing appetite/food intake—so it can support blood-glucose lowering and weight loss in conditions such as type 2 diabetes and obesity.To date, Tirzepatide is the only commercially available GLP-1/GIP dual receptor agonist product in the world.
GLP-1/GIP dual receptor agonists are reshaping the incretin field because they tackle a long-standing clinical and commercial pain point in metabolic care: achieving meaningful, sustained weight reduction and cardiometabolic improvement without forcing patients and providers into a tradeoff between efficacy, tolerability, and long-term adherence. By co-activating GLP-1 and GIP pathways in a single molecule, these therapies can deliver a broader metabolic effect than GLP-1 alone—supporting glucose control while driving appetite reduction and weight loss that can translate into improvements across obesity-linked comorbidities—while modern long-acting designs and carefully tuned receptor balance aim to preserve potency with manageable gastrointestinal burden and simpler dosing routines. Industry momentum is being driven by unprecedented demand for effective obesity and diabetes treatments, rising recognition of obesity as a chronic disease with downstream health-system costs, strong payer and employer interest in outcomes that reduce long-term risk, and rapid advances in peptide engineering, formulation, and device delivery that make scalable, patient-friendly products feasible. The market potential remains substantial as dual agonists expand from specialist-driven use toward broader chronic-care adoption, diversify into new formulations and delivery formats, and compete through differentiation on tolerability, durability of effect, and real-world outcomes, positioning the category as a durable growth engine within biopharma’s most strategically important therapeutic area.
The upstream raw materials for GLP-1/GIP Dual Receptor Agonist mainly include amino acids, condensation reagents, activators, resin carriers, etc. Typical raw material suppliers include Merck, Bachem, AAPPTec, Thermo Fisher, etc. The downstream applications are mainly in the treatment of obesity and diabetes.
The single-line production capacity of GLP-1/GIP dual receptor agonist varies significantly depending on the drug molecule type, process complexity, equipment scale, and production mode. Industry gross margins typically range from 60% to 80%.
This report is a detailed and comprehensive analysis for global GLP-1/GIP Dual Receptor Agonist market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global GLP-1/GIP Dual Receptor Agonist market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global GLP-1/GIP Dual Receptor Agonist market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global GLP-1/GIP Dual Receptor Agonist market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global GLP-1/GIP Dual Receptor Agonist market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for GLP-1/GIP Dual Receptor Agonist
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global GLP-1/GIP Dual Receptor Agonist market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly, Roche, Viking Therapeutics, Ascletis Pharma, Jiangsu Hengrui Medicine, East China Pharmaceutical, Tonghua Dongbao Pharmaceutical, Lepu Medical Technology, Hansoh Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
GLP-1/GIP Dual Receptor Agonist market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe GLP-1/GIP Dual Receptor Agonist product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of GLP-1/GIP Dual Receptor Agonist, with price, sales quantity, revenue, and global market share of GLP-1/GIP Dual Receptor Agonist from 2021 to 2026.
Chapter 3, the GLP-1/GIP Dual Receptor Agonist competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the GLP-1/GIP Dual Receptor Agonist breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and GLP-1/GIP Dual Receptor Agonist market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of GLP-1/GIP Dual Receptor Agonist.
Chapter 14 and 15, to describe GLP-1/GIP Dual Receptor Agonist sales channel, distributors, customers, research findings and conclusion.
In 2025, global GLP-1/GIP Dual Receptor Agonist production reached approximately 188.95 M Units, with an average global market price of around 175.26 USD per Unit.
A GLP-1/GIP dual receptor agonist is a single therapeutic agent (usually a peptide) designed to activate both the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR). By stimulating these two incretin pathways together, it aims to improve metabolic control—typically by enhancing glucose-dependent insulin secretion, reducing glucagon when appropriate, slowing gastric emptying, and decreasing appetite/food intake—so it can support blood-glucose lowering and weight loss in conditions such as type 2 diabetes and obesity.To date, Tirzepatide is the only commercially available GLP-1/GIP dual receptor agonist product in the world.
GLP-1/GIP dual receptor agonists are reshaping the incretin field because they tackle a long-standing clinical and commercial pain point in metabolic care: achieving meaningful, sustained weight reduction and cardiometabolic improvement without forcing patients and providers into a tradeoff between efficacy, tolerability, and long-term adherence. By co-activating GLP-1 and GIP pathways in a single molecule, these therapies can deliver a broader metabolic effect than GLP-1 alone—supporting glucose control while driving appetite reduction and weight loss that can translate into improvements across obesity-linked comorbidities—while modern long-acting designs and carefully tuned receptor balance aim to preserve potency with manageable gastrointestinal burden and simpler dosing routines. Industry momentum is being driven by unprecedented demand for effective obesity and diabetes treatments, rising recognition of obesity as a chronic disease with downstream health-system costs, strong payer and employer interest in outcomes that reduce long-term risk, and rapid advances in peptide engineering, formulation, and device delivery that make scalable, patient-friendly products feasible. The market potential remains substantial as dual agonists expand from specialist-driven use toward broader chronic-care adoption, diversify into new formulations and delivery formats, and compete through differentiation on tolerability, durability of effect, and real-world outcomes, positioning the category as a durable growth engine within biopharma’s most strategically important therapeutic area.
The upstream raw materials for GLP-1/GIP Dual Receptor Agonist mainly include amino acids, condensation reagents, activators, resin carriers, etc. Typical raw material suppliers include Merck, Bachem, AAPPTec, Thermo Fisher, etc. The downstream applications are mainly in the treatment of obesity and diabetes.
The single-line production capacity of GLP-1/GIP dual receptor agonist varies significantly depending on the drug molecule type, process complexity, equipment scale, and production mode. Industry gross margins typically range from 60% to 80%.
This report is a detailed and comprehensive analysis for global GLP-1/GIP Dual Receptor Agonist market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global GLP-1/GIP Dual Receptor Agonist market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global GLP-1/GIP Dual Receptor Agonist market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global GLP-1/GIP Dual Receptor Agonist market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global GLP-1/GIP Dual Receptor Agonist market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for GLP-1/GIP Dual Receptor Agonist
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global GLP-1/GIP Dual Receptor Agonist market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eli Lilly, Roche, Viking Therapeutics, Ascletis Pharma, Jiangsu Hengrui Medicine, East China Pharmaceutical, Tonghua Dongbao Pharmaceutical, Lepu Medical Technology, Hansoh Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
GLP-1/GIP Dual Receptor Agonist market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Balanced
- Biased
- Others
- Balanced
- Biased
- Others
- Long-acting
- Short-acting
- Diabetes
- Obesity
- Others
- Eli Lilly
- Roche
- Viking Therapeutics
- Ascletis Pharma
- Jiangsu Hengrui Medicine
- East China Pharmaceutical
- Tonghua Dongbao Pharmaceutical
- Lepu Medical Technology
- Hansoh Pharma
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe GLP-1/GIP Dual Receptor Agonist product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of GLP-1/GIP Dual Receptor Agonist, with price, sales quantity, revenue, and global market share of GLP-1/GIP Dual Receptor Agonist from 2021 to 2026.
Chapter 3, the GLP-1/GIP Dual Receptor Agonist competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the GLP-1/GIP Dual Receptor Agonist breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and GLP-1/GIP Dual Receptor Agonist market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of GLP-1/GIP Dual Receptor Agonist.
Chapter 14 and 15, to describe GLP-1/GIP Dual Receptor Agonist sales channel, distributors, customers, research findings and conclusion.
